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This paper describes the effect of increased expression of HO-1 protein and increased levels of HO activity on differentiation of
bone-marrow-derived human MSCs. MSCs are multipotent cells that proliferate and differentiate into many different cell types
including adipocytes and osteoblasts. HO, the rate-limiting enzyme in heme catabolism, plays an important role during MSCs
differentiation. HO catalyzes the stereospecific degradation of heme to biliverdin, with the concurrent release of iron and carbon
monoxide. Upregulation of HO-1 expression and increased HO activity are essential for MSC growth and differentiation to the
osteoblast lineage consistent with the role of HO-1 in hematopoietic stem cell differentiation. HO-1 participates in the MSC
differentiation process shifting the balance of MSC differentiation in favor of the osteoblast lineage by decreasing PPARγ and
increasing osteogenic markers such as alkaline phosphatase and BMP-2. In this paper, we define HO-1 as a target molecule in
the modulation of adipogenesis and osteogenesis from MSCs and examine the role of the HO system in diabetes, inflammation,
osteoporosis, hypertension, and other pathologies, a burgeoning area of research.
1. Background
1.1. Mesenchymal Stem Cells. Among cells bone-marrow-
derived MSCs have attracted a great deal of attention in
the past decade because of their high versatility. MSCs have
shown promise in the treatment of cardiovascular disease
in a series of animal models. Despite being a rare cell
population, MSCs can be extensively expanded in vitro thus
making them of potential use in the clinic [1]. Human
MSCs derived from bone marrow are multipotent cells that
differentiate and proliferate into many different cell types
in various tissues [1–3]. Bone marrow mononuclear cells
can be isolated with ease with a Ficoll-Paque PLUS density
gradient. HumanMSCs give rise to both osteoblastic and adi-
pogenic lineages when cultured with specific differentiation
media. The adipogenic media comprise of complete culture
medium supplemented with DMEM-high glucose, FBS,
insulin, dexamethasone, and indomethacin. The osteogenic
media contain ascorbic acid (for appropriate collagen and
extracellular matrix production) and β-glycerophosphate
(for appropriate mineralization). Several studies demon-
strated that an increase in the ROS leads to the elevation
of the levels of inflammatory cytokines in adipose tissue.
Oxidative stress is a major factor impairing MSCs function
resulting in decreased osteogenesis in favor of adipogenesis.
Whether MSCs differentiate into osteoblasts or adipocytes is
due to multiple signaling pathways including those heavily
influenced by HO-1 and -2 [4].
1.2. Role of HO during Bone Formation. Recent studies
have shown that several growth factors including OGP en-
hance differentiation of MSCs to osteoblasts [5] and that
EGF and OGP signaling pathways enhance osteoblast cell
proliferation. Osteogenic growth peptide is a naturally oc-
curring tetradecapeptide that is both an anabolic agent and
a hematopoietic stimulator [6]. For example, OGP increases
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osteoblast proliferation, AP activity, and matrix synthe-
sis and mineralization. It prevents glucocorticoid-induced
apoptosis and the subsequent bone remodeling alterations
that are associated with steroids [7]. Thus, role of HO
in the fluctuations of ROS and its effect on osteonectin
levels and in MSC-derived osteoblasts will be described.
Cytokines and HO activity have a regulatory role in MSCs
microenvironment and hematopoiesis [8]. HO attenuates
the overall production of ROS through its ability to degrade
the prooxidant, heme, resulting in the production of carbon
monoxide, biliverdin/bilirubin, and the release of free iron.
These three products of heme degradation play an important
role in signaling cascades, cell proliferation and differen-
tiation. HO is the enzyme that catalyzes the rate-limiting
step in the degradation of heme and exists in two forms:
the inducible HO-1 form and the constitutive HO-2 form
[4]. During fracture repair, activation of hypoxia-inducible
factor (HIF)-1 and its target genes, VEGF andHO-1, regulate
bone remodeling. Bone remodeling is a physiological process
which includes bone resorption (by osteoclasts) and bone
formation (by the osteoblasts) and requires coordination
of three cell types, osteocytes, osteoblasts, and osteoclasts.
During aging and in several pathologies, the rate of bone
turnover increases, but this is characterized by an impaired
osteoblastic bone formation compared to osteoclastic bone
resorption caused by decreased number and activity of
osteoblastic cells (Figure 1) [9–11].
This association suggests a role of HO-1 in bone metab-
olism. As previously stated, HO has strong implications in
bone marrow stem cell differentiation [8, 12]. Most notably,
HO-1 expression is increased during osteoblast stem cell
development. This increase in HO-1 expression precedes an
increase in alkaline phosphatase, bone morphogenic protein,
osteonectin, and RUNX-2 mRNA [13]. The function of
bone-specific alkaline phosphatase has been shown to be
that of a biochemical indicator of bone turnover. Upreg-
ulation of HO-1 increased MSC-mediated osteoblasts with
an associated decrease in adipocytes. OGP increased HO-
1 levels [13]. OGP also lead to an increase in pAKT, an
antiapoptotic protein, as well as an increase in eNOS and
p-eNOS (Figure 2) [13]. Past research has demonstrated
that eNOS is an enzyme expressed in osteoblasts that, when
deficient, has been shown to lead to a significant reduction
in bone formation in murine models [14]. Both eNOS and
NO are stimulators of BMP-2 and increase differentiation of
osteoblasts [15, 16]. IncreasedHO-1 expression has also been
shown to increase alkaline phosphatase as well as DNA accu-
mulation and mineralization when compared to osteoblasts
not treated with OGP [13]. Osteoblasts cultured in hyper-
glycemic conditions showed reduced levels of bone BMP-2,
osteonectin, pAMPK (a signaling molecule in osteoblasts),
and eNOS. The reduction of these osteogenic proteins and
enzymes was reversed by OGP which upregulated HO-1
with a subsequent increase in BMP-2, HO-1, eNOS, and
pAMPK [13]. HO-1 expression and activity are essential for
osteoblast differentiation from MSCs. Although basal levels
of HO-1 and HO activity are necessary for osteoblast growth,
an increase in HO-1 amplifies osteoblast differentiation.
Additionally, HO-1 is required to increase pAKT, pAMPK,
peNOS levels, and NO bioavailability [17, 18].
2. HO-1 and Oxidative Stress
An additional important association of HO-1 is this enzyme’s
influence on oxidative stress and reactive oxygen species
(ROS). Hyperglycemia and certain cytokines result in an
increase in ROS. HO-1 is inhibited in the presence of high
glucose. High glucose suppressed HO-1 expression in both
cell lines [19–21] and animal models [22–24].
Intracellularly, reduction-oxidation homeostasis is main-
tained by the balance between oxidants and antioxidants.
Antioxidants including HO, superoxide dismutase, glu-
tathione peroxidase, and catalase are endogenous. Exogenous
antioxidants are often derived from food and include vi-
tamins A, C, E, selenium, resveratrol, α-tocopherol, and
β carotene [25–27]. When the natural balance between
oxidants and antioxidants is altered, ROS can potentially
damage cellular structures like DNA, proteins, and phospho-
lipids. This process, called oxidative stress, is implicated in
several neurodegenerative and metabolic diseases including
obesity and type 2 diabetes. Moderate-to-severe obesity
is associated with an increased risk for hypertension and
insulin resistance in humans and animals [22, 28, 29].
The antioxidant effects of HO arise from its ability to
degrade heme from destabilized heme proteins and from
the production of biliverdin and bilirubin, products of HO
with potent antioxidant properties. Heme is a prooxidant
so, therefore, its breakdown is antioxidative. Although there
appears to be a convincingly clear link between HO-
1 and apoptosis, the specific mechanism through which
HO-1 prevents apoptosis remains unclear [21, 30, 31]. It
is likely that part of the anti-apoptotic role of HO-1 is
based on its function as an antioxidant enzyme. However,
the possibility remains that one or more of its products
play additional roles in anti-apoptotic mechanisms. This
association between a reduction in ROS with an increase in
HO-1 expression was demonstrated by treating MSCs with
CoPP, a strong inducer of HO-1. Exposure of the MSCs
to CoPP is effective in decreasing ROS while high glucose
concentrations increase ROS. A reduction in ROS permits
the restoration of osteoblast markers, specifically induction
of osteoprotegerin and osteocalcin [4].
The discovery that inhibition of HO-1 expression shifts
mesenchymal stem cells to favor adipocytic cells at the
expense of osteoblastic cells [4, 13] demonstrates that high
glucose has an adipogenic potential and also that a direct link
is present between HO-1 suppression and an increase in adi-
pogenesis [13]. The exact mechanisms through which HO-1
affects adipocyte and osteoblast differentiation and protects
against oxidative injury remain unclear. However, targeting
HO-1 expression is a gateway to increasing osteoblast stem
cell differentiation, decreasing oxidative stress, and to the
attenuation of osteoporosis through the promotion of bone
formation.
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Figure 1: Diagram representing the adverse effects of stress on bone, leading to the releases of inflammatory molecules.
2.1. Introduction of PPARγ and TZD. There appears to
be a strong link between HO-1 and PPARγ. PPARγ has
been found to increase with the suppression of HO-1 [13].
The increase in PPARγ is associated with a reduction of
HO-1 expression and coupled to a significant increase in
adipogenesis [13]. PPARγ is a transcription factor that has
been implicated in the development of osteoporosis. PPARγ
is considered to be the master regulator of adipogenesis
[32, 33], and its expression is believed to increase with
age and in diabetics. PPARγ is abundantly expressed in
mature adipocytes. Its levels are also increased in the
livers of animals that have developed steatosis [34, 35].
Loss of the gene that encodes for PPARγ in embryonic
fibroblasts results in the complete absence of adipogenesis
in murine studies [36]. In addition, adipocyte differentiation
can be stimulated by ectopic expression and activation
of PPARγ. Conversely, the absence of this gene results in
an increase in osteoblasts and bone mass [37]. PPARγ is
expressed in human MSCs [38–40]. This evidence coupled
with the fact that bone marrow fat increases and bone
marrow osteoblasts decrease with age in both animals and
humans [41, 42] demonstrates a possible strong link between
PPARγ and osteoporosis. Furthermore, PPARγ has been
found to decrease the levels of core-binding factor alpha
(Cbfa1) and RUNX-2, two factors needed for osteoblast
development. By leading to the differentiation of adipocytes
over osteoblasts, activation of PPARγ subsequently leads
to a decrease in bone mineral density and appears to be
strongly correlated to the development and progression of
osteoporosis. The stimulation of PPARγ occurs following
upregulation of PPARγ expression by TZD [43]. TZDs
provide diabetics with many benefits including lower blood
glucose levels and reduced rates of atherosclerosis. However,
these benefits come with multiple negative effects on bone
such as inhibiting osteoblast formation [44–46] and inducing
apoptosis of mature osteoblasts. Activation of PPARγ by
TZDs also results in the suppression of many vital osteogenic
transcription factors in both animal models and humans
[47, 48]. The end result of these antiosteogenic effects is
a decrease in bone mass. Furthermore, TZD use has been
shown to increase the risk of fracture in postmenopausal
women [49–51]. A large cohort study showed that the use
of TZDs in type 2 diabetics increased the fracture risk in
women over 65 years old. This increased fracture risk was
seen after only one year of TZD use [51]. The association
between TZD and fracture risk is likely due to a discrepancy
between bone formation and resorption as rosiglitazone, a
thiazolidinedione, has been found to decrease bone mass in
the hip and decrease serum osteocalcin levels [52]. Aging
leads to a decrease in HO-1 and an increase in bone marrow
adiposity with bone loss and an increase in the expression
of PPARγ and, ultimately, PPARγ [53]. Extensive research
demonstrates that PPARγ plays a pivotal role in regulating
MSC specification towards adipogenesis versus osteogenesis
and is instrumental in governing both bone mineral density
and osteoporosis.
2.2. HO-1 and CYP-450. HO-1 induction increased the lev-
els of cytochrome P450- (P450-) derived epoxyeicosatrienoic
acids (EETs), which further decreased PPARγ but increased
osteoblasts. We examined if EET levels regulate the MSC-
derived adipocytes. Expression of FAS and PPARγ levels
was significantly (P < 0.05) increased in preadipocyte
(14 days of MSC-derived adipocyte differentiation), and
conversely pACC and β-catenin were decreased (P <
0.05) in preadipocyte. The increase in FAS and PPARγ in
preadipocyte was suppressed by the EET. In contrast, the
EET treatments significantly increased both pACC and β-
catenin compared to cell treated with vehicle solutions.
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Figure 2: Effect of OGP onHO-1, peNOS/eNOS, and pAKT/AKT proteins expression after 21 days of osteoblast differentiation. Quantitative
densitometry evaluation of the proteins ratio was determined. Data are expressed as means ± SEM of three independent experiments;
∗P < 0.05 control versus OGP.
Further, MSCs-derived adipocyte exhibited a significantly
higher expression of PPARγ, SREBP-1, and GLUT4 com-
pared to MSCs-adipocyte grown in the presence of EET
[54]. Adipocyte cultured in the absence of the EET agonist
showed HO-1 levels that were decreased at day 10 and day
15 compared to adipocyte cultured in the presence of EET. In
contrast PPARγ and C/EBPα protein pattern was the reverse
by inhibition of HO-1. PPARγ and C/EBPα levels were sig-
nificantly increased, while Wnt/β-catenin protein levels were
decreased when compared with adipocytes cultured in the
presence of EET. EET-agonist-treated cells showed an in-
crease in β-catenin. HO-1 expression was greatly diminished
during adipogenic differentiation of MSCs, while FAS and
PPARγ levels increased. Ectopic expression and activation of
PPARγ are sufficient to induce adipocyte differentiation [33].
FAS mRNA levels increased dramatically during 3T3-L1
adipocyte differentiation [55]. In agreement with previous
studies, Wnt stimulation facilitates disruption of the axin-
based complex [56, 57]. This results in a decrease in the
phosphorylation of β-catenin, which enhances β-catenin
accumulation and activation leading to an arrest in adipo-
genesis at the early progenitor stage through the blocking
of PPARγ signaling [58, 59]. Furthermore, EETs inhibited
MSC-derived stem cell adipogenesis presumably through
activation of HO-1/Wnt/β-catenin and the expression of
C/EBPα, a marker of adipocyte differentiation [54]. In the
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Figure 3: Evaluation of lipid content measured as percentage of Oil Red O staining. (a) Representative photographs demonstrating an
increase in lipid droplets in the bone marrow of obese mice compared to lean mice and obese mice treated with CoPP. (b) Quantitative
analysis of bone marrow lipid content showing a significant increase in Oil Red O staining in the obese vehicle. Please note bars on the
graphs represent the mean ± SEM of three independent experiments; ∗P < 0.05 versus vehicle-treated lean mice; #P < 0.05 versus vehicle-
treated ob mice. (c) HO activity of bone marrow cells showing an increase in HO activity in both lean mice and obese mice treated with
CoPP when compared to obese mice not receiving treatment. Please note bars on the graphs represent the mean ± SEM of four independent
experiments; #P < 0.05 versus vehicle-treated leanmice; ∗P < 0.01 versus vehicle-treated obmice. (d) Superoxide generation in bonemarrow
cells is shown to be increased in obese mice and is lowest in the mice treated with CoPP implying an antioxidant effect of HO. Please note
bars on the graphs represent the mean ± SEM of four independent experiments; ∗P < 0.05 obese versus vehicle lean; #P < 0.001 versus
vehicle-treated obese.
present study, the increase of C/EBPα was prevented by
treatment of an EET agonist at day 10 and day 14. Vanella
and coworkers provided direct evidence that EET-agonist-
induced activation of HO-1 led to the increase in adiponectin
and phosphorylation/inactivation of ACC and consequently
decreased of FAS levels.
2.3. Diabetes and HO-1. Diabetes directly affects the
integrity and functionality of bone in both humans and
animals resulting in osteoporosis and an increase in adi-
pogenesis [60–64]. Patients with diabetes frequently have a
lower bone mineral density with associated osteopenia or
osteoporosis. Because diabetic individuals commonly have
decreased bone mass and bone mineral density, they are
more susceptible to fractures and impaired bone healing.
This correlation between diabetics and an increase in
fractures has been well documented in the literature. A large
prospective cohort study of over 32,000 postmenopausal
women found that those with type 1 diabetes mellitus were
12 times more likely to experience hip fractures than those
women without type 1 diabetes. Women with type 2 diabetes
had a 1.7-fold increase in hip fractures when compared to
women without this disease [65]. Prevention at decreasing
osteoporotic fractures in patients with diabetes can involve
strict glucose control, prevention and treatment of vascular
complications, regular exercise, and fall prevention [66].
Additionally, biochemical markers of bone turnover are
negatively affected in diabetics [67]. One such biomechanical
marker, osteocalcin, has been found to be decreased in
patients with diabetes [68]. However, the exact pathogenesis
of the reduction in bone mass seen in diabetics is unknown.
Also, the effect of osteoblast stem cell differentiation under
high glucose conditions has not been fully elucidated
although, as previously stated, strong evidence supports the
belief that hyperglycemic environments decrease osteoblast
differentiation and increase adipocyte differentiation [4, 13].
Upregulation of HO-1 expression in obesity and type 2
diabetes results in a decrease in visceral and subcutaneous fat
content, improved insulin sensitivity, and increased insulin
receptor phosphorylation [22, 69–71]. MRI studies showed
that upregulation of HO-1 decreased adiposity and adipocyte
hypertrophy [17, 70]. The decrease in HO-1 expression was
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Figure 4: Effect of CoPP on MSC-derived adipogenesis. Adipogenesis was measured as the relative absorbance of Oil Red O at day 10.
(a) Representative pictures demonstrating an increase in lipid droplets in the MSC of obese mice compared to lean mice and obese mice
treated with CoPP. (b) Quantitative analysis of adipogenesis showing a significant increase in Oil Red O staining in the obese MSC-derived
adipocytes. Data are expressed as mean ± SE (∗P < 0.01 obese versus CoPP). Note: unpublished data.
associated with an impairment in the mesenchymal stem
cells production of adiponectin and increased adipogenesis
[13, 22]. In addition, HO-1 gene expression has a differ-
ential effect on osteoblasts and adipocyte cell proliferation
and differentiation [4, 13]. EETs administration decreased
adiposity and insulin resistance in mice and rat models of
obesity and diabetes via an increase in HO-1 gene expression
and signaling cascade including the activation of AMPK and
pAKT [72–74]. Sacerdoti and coworkers [75, 76] studied
the interactions between HO-1 gene expression and EETs
in vitro and showed that EETs induce HO-1 protein and
HO activity. Human stromal-mesenchymal stem cells express
CYP450 monooxygenase and form EETs and 20-HETE [8].
Not only 20-HETE but other eicosanoids are correlated with
the progression of diabetes [77, 78] as well.
MSCs have the ability to metabolize arachidonic acid to
HETE at comparable levels to endothelial cells. Additionally,
the EET agonist (NUDSA) inhibited soluble epoxide hydro-
lase (sEH) and reduced the rate of body weight gain in obese
mice which was accompanied by an increase in HO-1 expres-
sion [73, 79]. EET crosstalks with HO-1 on the decrease of
adipogenesis [54]. The ability of hyperglycemic conditions
and diabetes to activate adipocytes to undergo adipogenic
differentiation appears to be strongly influenced on the
suppression of HO-1. Therefore, it seems that osteoblast
differentiation under hyperglycemic conditions decreases
secondary to this suppression of HO-1. In addition, high
levels of glucose lead to an increase in reactive oxygen species
which have been shown to block BMP-2, osteonectin, osteo-
protegerin and osteocalcin [4]. A 2010 study used osteoblast-
like MG63 cells to demonstrate that hyperglycemic condi-
tions significantly suppressed cell growth, mineralization,
and expression of multiple osteoblastic markers (RUNX-2,
osteocalcin, osteonectin, type 1 collagen). These high glucose
conditions simultaneously stimulated the expression of
PPARγ, adipocyte fatty-acid-binding protein (aP2), resistin,
and adipsin, all markers of adipogenesis [4].
An additional unpublished study by the authors provides
evidence that obese mice have a significant increase in bone
marrow adipocytes when compared to both lean mice and
obese mice treated with the potent HO-1 inducer CoPP
(Figures 3(a), 3(b), and 4). The HO activity in the bone
marrow was significantly lower in obese mice compared to
lean mice. However, CoPP treatment did increase the HO
activity in obese mice (Figure 3(c)). Lastly, superoxide levels
were increased in obese mice compared to lean mice. CoPP
treatment to obese mice decreased these elevated superoxide
levels (Figure 3(d)).
Furthermore, hyperglycemia has been shown to promote
cell death in many cell types such as endothelial and
mesangial cells [19, 80, 81]. Oxidative stress is a conse-
quence of hyperglycemia that can induce apoptosis via sig-
naling and/or outright molecular damage. In streptozotocin-
(STZ-) induced diabetic rats, symptoms of oxidative stress,
including increases in cellular heme and apoptosis, were
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Figure 5: Schematic demonstrating the interplay between HO-1, hyperglycemia, ROS, and PPAR-γ on the regulation of osteoblast and
adipocyte differentiation from mesenchymal stem cells.
found to be reversed by upregulation of HO-1 [23]. Elevated
glucose levels cause glucose oxidation which leads to an
increase of ROS in endothelial cells. This formation of
ROS is believed to be the major factor in endothelial
dysfunction such as abnormalities in cell cycling and delayed
replication. However, these abnormalities are able to be
reversed by antioxidant agents and an increased expression
of antioxidant enzymes. Overexpression of HO-1 has been
shown to make cells resistant to oxidative stress-causing
agents while enhancing cell growth and angiogenesis. Such
findings further demonstrate the important cytoprotective
and antioxidant role of HO-1. Strong evidence exists that
diabetic-induced hyperglycemia has a substantial impact
on the development and progression of osteoporosis. The
stimulation of osteoblast apoptosis as well as the decrease
in osteoblast and increase in adipocyte differentiation all
contribute to the decreased bone mineral density observed
in individuals with diabetes.
2.4. Future Perspectives. Osteoporosis is a complex con-
dition with significant morbidity, characterized by low
bone mass, increased fragility, and fracture risk. Although
mechanisms are unclear, there is significant evidence show-
ing the interplay between HO-1, PPARγ, oxidative stress,
and hyperglycemia. All have a role in the regulation of
mesenchymal stem cell differentiation and the development
of osteoporosis (Figure 5). Several studies have shown that
HO-1 plays a considerable role in reducing oxidative stress,
cellular apoptosis, increasing osteoblast differentiation, while
simultaneously suppressing adipocyte differentiation from
mesenchymal stem cells. HO-1 upregulation causes an
increase in alkaline phosphatase and BMP-2 expression and
a decrease in PPARγ expression, increasing bone formation
and decreasing adipocyte differentiation. Conversely, HO-1
suppression upregulates PPARγ and increases adipogenesis,
worse in diabetics, with reduced bone mineral density.
Pharmacological and genetic approaches to deliver HO-1 or
products of heme degradation remain to be elucidated for
the causes, treatment, and prevention of osteoporosis.
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